bocouture 50unit powder for solution for injection vials
merz pharma uk ltd - botulinum toxin type a - powder for solution for injection - 50unit
dysport 300unit powder for solution for injection vials
ipsen ltd - botulinum toxin type a - powder for solution for injection - 300unit
xeomin 50unit powder for solution for injection vials
merz pharma uk ltd - botulinum toxin type a - powder for solution for injection - 50unit
bocouture 100unit powder for solution for injection vials
merz pharma uk ltd - botulinum toxin type a - powder for solution for injection - 100unit
dysport powder lyophilized for solution for injection
ipsen biopharm limited - clostridium botulinum type a toxin-haemagglutinin complex - powder lyophilized for solution for injection - 500u
bocouture 50 units powder for solution for injection
merz pharmaceuticals gmbh eckenheimer landstrasse 100, d-60318 frankfurt am main, germany - botulinum toxin, type a - powder for solution for injection - botulinum toxin type a 50 u - muscle relaxants
bocouture 100 units powder for solution for injection
merz pharmaceuticals gmbh eckenheimer landstrasse 100, d-60318 frankfurt am main, germany - botulinum toxin, type a - powder for solution for injection - botulinum toxin type a 100 u - muscle relaxants
nuceiva
evolus pharma b.v. - botulinum toxin type a - skin aging - other muscle relaxants, peripherally acting agents - temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown (glabellar lines), when the severity of the above facial lines has an important psychological impact in adults below 65 years of age.
dysport 300
medison pharma ltd - botulinum toxin type a - powder for solution for injection - botulinum toxin type a 300 u/vial - botulinum toxin - dysport is indicated for symptomatic treatment of focal spasticity of:- upper limbs in adults due to stroke or traumatic brain injury- lower limbs in adults affecting the ankle joint due to stroke or traumatic brain injury (tbi) - dynamic equinus foot deformity in ambulant paediatric cerebral palsy patients, two years of age or older.- upper limbs in pediatric cerebral palsy patients, two years of age or older.dysport is indicated in adults for symptomatic treatment of:- spasmodic torticollis- blepharospasm- hemifacial spasm.dysport is indicated for symptomatic treatment of persistent severe primary hyperhidrosis of the axillae, which interferes with the activities of daily living and is resistant to topical treatment.dysport is indicated for the temporary improvement in the appearance of moderate to severe:- glabellar lines (vertical lines between the eyebrows) seen at frown,and/or - lateral canthal lines (crow’s feet lines) seen at maximum smile in adult patients under 65 years, when the severity of these lines has an important psychological impact on the patient.
dysport 500
medison pharma ltd - botulinum toxin type a - powder for solution for injection - botulinum toxin type a 500 u/vial - botulinum toxin - dysport is indicated for symptomatic treatment of focal spasticity of:- upper limbs in adults due to stroke or traumatic brain injury- lower limbs in adults affecting the ankle joint due to stroke or traumatic brain injury (tbi) - dynamic equinus foot deformity in ambulant paediatric cerebral palsy patients, two years of age or older.- upper limbs in pediatric cerebral palsy patients, two years of age or older.dysport is indicated in adults for symptomatic treatment of:- spasmodic torticollis- blepharospasm- hemifacial spasm.dysport is indicated for symptomatic treatment of persistent severe primary hyperhidrosis of the axillae, which interferes with the activities of daily living and is resistant to topical treatment.dysport is indicated for the temporary improvement in the appearance of moderate to severe:- glabellar lines (vertical lines between the eyebrows) seen at frown,and/or - lateral canthal lines (crow’s feet lines) seen at maximum smile in adult patients under 65 years, when the severity of these lines has an important psychological impact on the patient.